NeuroPace's (NPCE) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Analysts at Weiss Ratings have reaffirmed their "sell (D-)" rating for NeuroPace (NASDAQ:NPCE), suggesting ongoing concerns about the company's performance.
• The stock has an average rating of "Moderate Buy" with a consensus price target of $16.60, despite recent downgrades from other analysts.
• NeuroPace reported a loss of $0.26 per share for Q2, missing expectations, while its revenue of $23.52 million exceeded analysts' estimates.

NeuroPace (NASDAQ:NPCE - Get Free Report)'s stock had its "sell (d-)" rating reissued by analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently issued reports on the stock. Zacks Research cut shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Wells Fargo & Company cut their target price on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.60.

NeuroPace Stock Performance

Shares of NPCE opened at $11.13 on Wednesday. The firm has a 50-day moving average of $9.53 and a 200-day moving average of $11.02. NeuroPace has a one year low of $5.45 and a one year high of $18.98. The company has a market cap of $368.18 million, a PE ratio of -13.25 and a beta of 1.91. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that NeuroPace will post -1 earnings per share for the current year.

Institutional Trading of NeuroPace

Several hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC acquired a new stake in NeuroPace in the 1st quarter worth about $19,468,000. Armistice Capital LLC increased its holdings in NeuroPace by 94.7% in the 1st quarter. Armistice Capital LLC now owns 1,153,614 shares of the company's stock valued at $14,178,000 after buying an additional 561,000 shares during the period. Deutsche Bank AG increased its holdings in NeuroPace by 124.0% in the 1st quarter. Deutsche Bank AG now owns 924,274 shares of the company's stock valued at $11,359,000 after buying an additional 511,662 shares during the period. Driehaus Capital Management LLC bought a new position in NeuroPace in the 1st quarter valued at about $9,874,000. Finally, Geode Capital Management LLC increased its holdings in NeuroPace by 44.6% in the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company's stock valued at $5,406,000 after buying an additional 149,595 shares during the period. Institutional investors and hedge funds own 78.83% of the company's stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.